Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 207

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor

Albert, Daniel H., Tapang, Paul, Magoc, Terrance J., Pease, Lori J., Reuter, David R., Wei, Ru-Qi, Li, Junling, Guo, Jun, Bousquet, Peter F., Ghoreishi-Haack, Nayereh S., Wang, Baole, Bukofzer, Gail T., Wang, Yi-Chun, Stavropoulos, Jason A., Hartandi, Kresna, Niquette, Amanda L., Soni, Nirupama, Johnson, Eric F., McCall, J. Owen, Bouska, Jennifer J., Luo, Yanping, Donawho, Cherrie K., Dai, Yujia, Marcotte, Patrick A., Glaser, Keith B., Michaelides, Michael R., Davidsen, Steven K. · 2006 · Molecular Cancer Therapeutics

Abstract

ABT-869 is a structurally novel, receptor tyrosine kinase (RTK) inhibitor that is a potent inhibitor of members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families (e.g., KDR IC50 = 4 nmol/L) but has much less activity (IC50s > 1 μmol/L) against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. The inhibition profile of ABT-869 is evident in cellular assays of RTK phosphorylation (IC50 = 2, 4, and 7 nmol/L for PDGFR-β, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC50 = 0.2 nmol/L for human endothelial cells). ABT-869 is not a general antiproliferative agent because, in most cancer cells, >1,000-fold higher concentrations of ABT-869 are required for inhibition of proliferation. However, ABT-869 exhibits potent antiproliferative and apoptotic effects on cancer cells whose proliferation is dependent on mutant kinases, such as FLT3. In vivo ABT-869 is effective orally in the mechanism-based murine models of VEGF-induced uterine edema (ED50 = 0.5 mg/kg) and corneal angiogenesis (>50% inhibition, 15 mg/kg). In tumor growth studies, ABT-869 exhibits efficacy in human fibrosarcoma and breast, colon, and small cell lung carcinoma xenograft models (ED50 = 1.5–5 mg/kg, twice daily) and is also effective (>50% inhibition) in orthotopic breast and glioma models. Reduction in tumor size and tumor regression was observed in epidermoid carcinoma and leukemia xenograft models, respectively. In combination, ABT-869 produced at least additive effects when given with cytotoxic therapies. Based on pharmacokinetic analysis from tumor growth studies, efficacy correlated more strongly with time over a threshold value (cellular KDR IC50 corrected for plasma protein binding = 0.08 μg/mL, ≥7 hours) than with plasma area under the curve or Cmax. These results support clinical assessment of ABT-869 as a therapeutic agent for cancer. [Mol Cancer Ther 2006;5(4):995–1006]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-05-0410

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 207

Metadata

Authors
Albert, D. H., Tapang, P., Magoc, T. J., Pease, L. J., Reuter, D. R., Wei, R.-Q., Li, J., Guo, J., Bousquet, P. F., Ghoreishi-Haack, N. S., Wang, B., Bukofzer, G. T., Wang, Y.-C., Stavropoulos, J. A., Hartandi, K., Niquette, A. L., Soni, N., Johnson, E. F., McCall, J. O., Bouska, J. J., Luo, Y., Donawho, C. K., Dai, Y., Marcotte, P. A., Glaser, K. B., Michaelides, M. R., & Davidsen, S. K.
Venue
Molecular Cancer Therapeutics
Published
2006-04-01
Volume
5
Issue
4
Pages
995-1006
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W922724308
Cited by
207
References
6
FWCI
4.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. https://app.cochat.ai/papers/10.1158/1535-7163.mct-05-0410
The paper
Albert, D. H., Tapang, P., Magoc, T. J., Pease, L. J., Reuter, D. R., Wei, R.-Q., Li, J., Guo, J., Bousquet, P. F., Ghoreishi-Haack, N. S., Wang, B., Bukofzer, G. T., Wang, Y.-C., Stavropoulos, J. A., Hartandi, K., Niquette, A. L., Soni, N., Johnson, E. F., McCall, J. O., . . . Davidsen, S. K. (2006). Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-05-0410

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.